Startup Genia Sees Diagnostic Potential for Nanopore Sequencing Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genia, a Mountain View, Calif.-based startup, is developing a semiconductor-based nanopore sequencing platform that it believes will show promise for molecular diagnostic applications.

Stefan Roever, CEO and founder of the company, told GenomeWeb Daily News this week that the company has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.